Thus, multiple open questions arose defining the use of ICB in BC, including appropriate TIL and PD-L1 expression assessment, the selection of the ideal chemotherapy partner to maximize therapeutic efficacy, other biomarker discovery for patient stratification, and their predictive value in luminal tumors, where late recurrences are common. The gene discussed is CD274; the disease is breast cancer.